|本期目录/Table of Contents|

卵巢癌组织中生存素的表达及临床意义的Meta分析

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3682-3689
栏目:
论着(妇科肿瘤)
出版日期:
2019-09-08

文章信息/Info

Title:
Expression and clinical significance of Survivin in tissues of ovarian cancer:A Meta-analysis
作者:
龚 钿;?赵红利;?王建华;?杨 琴
眉山市人民医院妇产科,四川 眉山 620100
Author(s):
Gong Tian;?Zhao Hongli;?Wang Jianhua;?Yang Qin
Department of Obstetrics and Gynecology,Meishan People's Hospital,Sichuan Meishan 620100,China.
关键词:
Survivin;?卵巢癌;?Meta分析;?病例-对照研究
Keywords:
Survivin;?ovarian cancer;?Meta-analysis;?case-control study
分类号:
R737.31
DOI:
10.3969/j.issn.1672-4992.2019.20.031
文献标识码:
A
qq自动领红包软件:
目的:系统评价卵巢癌组织中生存素(Survivin)的表达水平及其与临床病理特征的关系。方法:计算机检索各种数据库,寻找与本研究相关的国内外文献,搜集卵巢癌组织中Survivin表达及其与临床病理特征关系的病例-对照研究。根据本研究要求进行筛选,排除不适合文献,对各项数据进行总结,利用计算机软件进行统计分析,最终获得结论。结果:纳入30个研究,其中卵巢癌患者1 472例,卵巢良性病变患者663例,正常对照组371例。Meta分析结果显示:Survivin在卵巢癌组和正常对照组[OR=33.70,95%CI(21.41,53.05),P<0.000 01]、卵巢癌组和卵巢良性病变组[OR=12.17,95%CI(9.55,15.53),P<0.000 01]、临床分期Ⅰ-Ⅱ期组与Ⅲ-Ⅳ期组[OR=0.16,95%CI(0.12,0.22),P<0.000 01]、临床分级G1-G2级组与G3级组[OR=0.19,95%CI(0.14,0.26),P<0.000 01]、伴淋巴结转移组和无淋巴结转移组[OR=5.89,95%CI (2.37,14.66),P=0.000 1]、伴腹水组和无腹水组[OR=5.63,95%CI(1.64,19.28),P=0.006]表达差异均有统计学意义。但在卵巢癌患者年龄>50岁组和≤50岁组
[OR=0.82,95%CI(0.47,1.43),P=0.47]表达差异无统计学意义。结论:Survivin表达与卵巢癌及其临床病理特征明显相关,由此可见其有可能参与卵巢癌的整个过程当中。由于所选择文献相对有限,结论仍需进一步验证,希望有更大样本研究参与其中,获得更可靠结果。
Abstract:
Objective:To systematically evaluate the expression of Survivin in ovarian cancer and its relationship with clinicopathological features.Methods:Various databases were searched by computer.Domestic and foreign literatures related to this study were searched,and case-control studies on the relationship between Survivin expression and clinicopathological features in ovarian cancer tissues were collected.According to the requirements of this study,unsuitable literatures were excluded.various data were summarized.Statistical analysis was did by using computer software.Results:Thirty studies were included,of which 1 472 were ovarian cancer patients,663 were benign ovarian lesions,and 371 were normal controls.Meta-analysis showed that there was significant difference for Survivin in ovarian cancer and normal control group OR=33.70,95%CI(21.41,53.05),P<0.000 01],ovarian cancer group and benign ovarian disease group [OR=12.17,95%CI( 9.55,15.53),P<0.000 01],clinical stages I-II and III-IV group [OR=0.16,95%CI(0.12,0.22),P<0.000 01],clinical grade G1-G2 group and G3 group[OR=0.19,95%CI(0.14,0.26),P<0.000 01],lymph node metastasis group and no lymph node metastasis group [OR=5.89,95%CI (2.37,14.66),P=0.000 1],ascites group and ascites group[OR=5.63,95%CI(1.64,19.28),P=0.006].However,there was no significant difference in the expression of ovarian cancer patients> 50 years old group and ≤50 years old group [OR=0.82,95%CI(0.47,1.43),P=0.47].Conclusion:The expression of Survivin is significantly associated with ovarian cancer and its clinicopathological features.It can be seen that it may be involved in the entire process of ovarian cancer.Since the selected literature is relatively limited,the conclusions still need to be further verified.It is hoped that more sample studies will be involved to obtain more reliable results.

参考文献/References

[1] SHAO T,ZHANG XY,WANG N,et al.expression and clinical significance of ERR α and AROM in epithelial ovarian carcinoma [J].Continuing Medical Education in China,2018,10(34):73-76.[邵婷,张雪英,王宁,等.ERRα和AROM在上皮性卵巢癌中的表达及临床意义[J].中国继续医学教育,2018,10(34):73-76.]
[2] QU Xiaohui,DENG Yinghui.Expression of TGF- β 1 in ovarian serous adenocarcinoma and its clinical significance [J].Jiangxi Medicine,2018,53(11):1215-1218.[屈晓辉,邓颖辉.TGF-β1在卵巢浆液性腺癌中的表达及其临床意义[J].江西医药,2018,53(11):1215-1218.]
[3] DENG Ziwei,QIU Chengfeng,WANG Hongqiang,et al.Evaluation of the literature quality of allicin used in the prevention and treatment of pulmonary infection [J].Pharmacology,2017,29 (05):44-46.
[4] Sui L,Dong Y,Ohno M,et al.Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors[J].Int J Oncol,2002,21(2):315-320.
[5]WANG Yankui,YANG Jinzhi,LUO Bin,et al.Survivin expression and its significance in epithelial ovarian cancer [J]. Chinese obstetrics and gynecology,2003,5(15):368-372,401.[王言奎,杨锦芝,罗兵,等.上皮性卵巢癌中Survivin的表达及意义[J].中国妇产科临床,2003,5(15):368-372,401.]
[6] SHI Huirong,LAN Li,QIAO Yuhuan,et al.Expression of Survivin and PCNA in ovarian carcinoma [J].Journal of Zhengzhou University (Medical Edition),2004,39(4):552-554.[史惠蓉,兰莉,乔玉环,等.卵巢癌组织中Survivin和PCNA的表达[J].郑州大学学报(医学版),2004,39(4):552-554.]
[7] YIN Rutie,PENG Zilan,YANG Kaixuan,et al.Expression and significance of Survivin protein in ovarian cancer [J].Journal of Sichuan University:Medical Edition,2006,37(2):215-217.[尹如铁,彭芝兰,杨开选,等.Survivin蛋白在卵巢癌中的表达和意义[J].四川大学学报:医学版,2006,37(2):215-217.]
[8] SHEN Aifang,YANG Xingsheng,CHEN Bing,et al.The expression of Ki-67 antigen and Survivin gene in epithelial ovarian cancer was enhanced and correlated [J].Basic Medicine and Clinic,2006,31(03):312-314.[申爱方,杨兴升,陈冰,等.Ki-67抗原和Survivin基因在上皮性卵巢癌中表达增强且相关[J].基础医学与临床,2006,31(03):312-314.]
[9] JIN Rong,LI YM,JIAO Tong,et al.Expression of Survivin gene protein,microvessel density in ovarian cancer and its relationship with CPA blood flow [J].Chinese Medical Imaging Technology,2006,25(12):1883-1886.[金蓉,李彦敏,焦彤,等.Survivin基因蛋白、微血管密度在卵巢癌中的表达与CPA血流的关系[J].中国医学影像技术,2006,25(12):1883-1886.]
[10] MIAO Hui.Expression of Survivin protein in epithelial ovarian carcinoma and the effect of topotecan on its expression [J].Int J Oncology,2006,33(12):945-947.[苗卉.上皮性卵巢癌Survivin蛋白的表达及拓扑替康对其表达的影响[J].国际肿瘤学杂志.2006,33(12):945-947.]
[11] GAO Qing,XING Lanying,WANG Yongxue.Expression of P-glycoprotein and Survivin protein in epithelial ovarian carcinoma and its relationship with drug resistance of ovarian cancer [J].Xi'an Jiaotong University(Medical edition),2007,16(05):578-581.[高庆,邢兰英,王咏雪.P-糖蛋白、Survivin蛋白在卵巢上皮性癌中的表达及其与卵巢癌耐药的关系[J].西安交通大学学报(医学版),2007,16(05):578-581.]
[12] HAN Fengxian,ZHANG Shiqian.Expression of Survivin in ovarian cancer and its relationship with diagnosis,treatment and prognosis [J].Maternal and Child Health care in China,2007,22(34):4922-4924.[韩风贤,张师前.Survivin在卵巢癌中的表达及其与诊疗、预后关系的研究[J].中国妇幼保健,2007,22(34):4922-4924.]
[13] LI Jichun,HE Ling.Expression of Survivin and its clinical significance in ovarian carcinoma [J].Ningxia Medical Journal,2008,30 (1):41-43.[李际春,何玲.卵巢癌组织中Survivin的表达及其临床意义[J].宁夏医学杂志,2008,30(1):41-43.]
[14] WANG Shichao,LI Xiao,ZHANG Xiaoping,et al.Expression and correlation of Survivin protein and VEGF in epithelial ovarian carcinoma [J].Maternal and Child Health Care in China,2008,23(20):2877-2879.[王仕超,李萧,张小平,等.Survivin蛋白和VEGF在上皮性卵巢癌中的表达及相关性[J].中国妇幼保健,2008,23(20):2877-2879.]
[15] CHEN Ruijun,HU Jianming.Expression of C-erbB-2 cyclin B1 and Survivin in benign and epithelial ovarian carcinoma and its clinical significance [J].Chinese and Foreign Health Abstracts:Clinicians,2008,19(8):32-36.[陈睿君,胡建铭.C-erbB-2,cyclinB1和Survivin在卵巢良性肿瘤及上皮性卵巢癌组织的表达及其临床意义[J].中外健康文摘:临床医师,2008,19(8):32-36.]
[16] LIAO Qi,ZHEN Zhuo,DU Shaomin,et al.Expression and significance of CA125,Survivin and Ki67 in epithelial ovarian carcinoma [J].Chinese Practical Medicine,2009,4(04):113.[廖琪,真酌,杜绍敏,等.CA125、Survivin和Ki67在上皮性卵巢癌中表达及意义[J].中国实用医药,2009,4(04):113.]
[17] LI Yan,CHANG Shulan.Expression of Survivin in ovarian carcinoma and its correlation with p53 expression [J].Chinese Journal of Modern Medicine,2009,19(5):684-686.[李妍,张淑兰.Survivin在卵巢癌组织中的表达及其与p53表达相关性的研究[J].中国现代医学杂志,2009,19(5):684-686.]
[18] LI Lin,ZHOU Min,YAO Bin,et al.The expression of Survivin in ovarian cancer is associated with chemotherapeutic resistance and prognosis [J].Chinese Journal of Modern Medicine,2009,11(6):24-27.[李琳,周敏,姚彬,等.Survivin在卵巢癌中的表达与化疗耐药和预后关系[J].中国现代医药杂志,2009,11(6):24-27.]
[19] WANG Guifang,YANG Xiaojia,MAO Rongjun.Expression of S100A4 PDGF-A KLK6 and Survivin in ovarian cancer [J].Journal of Practical Medical Techniques,2009,16(01):11-14.[王桂芳,杨小佳,毛荣军.S100A4 PDGF-A KLK6及Survivin在卵巢癌中的表达[J].实用医技杂志,2009,16(01):11-14.]
[20] TIAN Dongyan,WANG Dehua,LIU Yonghong,et al.Expression and correlation of Survivin and CyclinD1 in Ovarian Cancer [J].Journal of Tianjin Medical University,2009,15(1):81-83.[田冬艳,王德华,刘永红,等.Survivin和CyclinD1在卵巢癌中的表达和相关性[J].天津医科大学学报,2009,15(1):81-83.]
[21] QI Shifang,DUAN Wenyan,TIAN Xiaoyu,et al.Expression and correlation analysis of TRAIL and Survivin in ovarian carcinoma [J].Tianjin Medicine,2009,37(10):886-887.[戚世芳,段文艳,田晓予,等.TRAIL和Survivin在卵巢癌组织中的表达及其相关性分析[J].天津医药,2009,37(10):886-887.]
[22] CAI Hongxing,LI Zhouru,CHENG Yanbo,et al.Expression and clinical significance of Survivin in ovarian cancer [J].Shandong Medicine,2009,49(48):42-43.[蔡红星,李周儒,程言博,等.Survivin在卵巢癌中的表达及其临床意义[J].山东医药,2009,49(48):42-43.]
[23] ZHANG Chunnian,WANG Jianzhong.Expression of Survivin and Caspase-3 in epithelial ovarian cancer and the effect of chemotherapy on them [J].Journal of Gannan Medical College,2010,20(03):372-374.[张春年,王建中.Survivin与Caspase-3在上皮性卵巢癌中的表达及化疗对其的影响[J].赣南医学院学报,2010,20(03):372-374.]
[24] REN Mei,HE Li.Expression of apoptosis suppressor genes Survivin and BAG-1 in epithelial ovarian carcinoma [J].Chinese Community Physician (medical specialty),2011,47(13):263.[任美,何俐.凋亡抑制基因Survivin和BAG-1在上皮性卵巢癌中的表达[J].中国社区医师(医学专业),2011,47(13):263.]
[25] MA Zhisong,HUANG Yongsheng,SU Yue.Expression of survivin and p53 in epithelial ovarian carcinoma [J].Journal of Practical Medicine,2011,28 (4):301-302.[马志松,黄永生,苏悦.卵巢上皮性癌组织中survivin与p53表达的研究[J].实用医药杂志,2011,28(4):301-302.]
[26] XUAN Zhangbiao,HONG Lihua.Expression of FHIT,survivin,PTEN in epithelial ovarian carcinoma and its clinical significance [J].Journal of Medical Research,2011,28(07):133-136.[宣樟标,洪丽华.FHIT、survivin、PTEN在上皮性卵巢癌中的表达及其临床意义[J].医学研究杂志,2011,28(07):133-136.]
[27] YANG Qiongjiao,XU Shuyuan,HUANG Xiaoming,et al.Expression of RUNX3 and Survivin in epithelial ovarian carcinoma and its clinical significance [J].Journal of Clinical and Experimental Medicine,2011,10(2):87-89.[杨琼娇,许淑媛,黄晓明,等.RUNX3和Survivin在卵巢上皮性癌中的表达及其临床意义[J].临床和实验医学杂志,2011,10(2):87-89.]
[28] WANG Peijun,YUAN Dexin,HAN Shuyun,et al.Expression of aquaporin 1 and Survivin in ovarian carcinoma and its clinical significance [J].Heilongjiang Medical Science,2011,34(2):40-41.[王培军,原德新,韩淑云,等.水通道蛋白1和Survivin在卵巢癌组织中的表达及其临床意义[J].黑龙江医药科学,2011,34(2):40-41.]
[29] HUANG Xiaochun,DAI Weidong.Expression of Survivin and Smac in ovarian epithelial tumors and their correlation [J].Journal of Yan 'an University:Medical Science Edition,2011,9(1):3-6.[黄晓春,代维栋.Survivin与Smac在卵巢上皮性肿瘤中的表达及其相关性研究[J].延安大学学报:医学科学版,2011,9(1):3-6.]
[30] GUAN YL,YANG H,Wang YP,et al.Expression and significance of Survivin,PKA in epithelial ovarian carcinoma [J].Chinese Contemporary Medicine,2013,20(22):89-90,92.[管艳玲,杨寒,王玉萍,等.Survivin、PKA在上皮性卵巢癌组织中的表达及意义[J].中国当代医药,2013,20(22):89-90,92.]
[31] Turan G,Usta CS,Usta A,et al.The expression of HER-2/neu (c-erbB2),survivin and cycline D1 in serous ovarian neoplasms:their correlation with clinicopathological variables[J].Journal of Molecular Histology,2014,24(1):44-49.
[32] LONG Qiongxian,WU Cailiang,TANG Zhirong,et al.Correlation and significance of survivin and VEGF-C protein expression in epithelial ovarian carcinoma [J].Advances in Modern Obstetrics and Gynaecology,2015,24(1):64-68.[龙琼先,吴才良,唐治蓉,等.卵巢上皮性癌中survivin和VEGF-C蛋白表达的相关性及意义[J].现代妇产科进展,2015,24(1):64-68.]
[33] LIU Sichao,WU Jinfang.Expression of Survivin,MMP-2 and p16 protein in epithelial ovarian carcinoma and its clinical significance[J].Shaanxi Medical Journal,2015,44(4):497-499.[刘嗣超,邬晋芳.Survivin、MMP-2及p16蛋白在卵巢上皮癌中的表达及其临床意义[J].陕西医学杂志,2015,44(4):497-499.]
[34] Geng Juan,Lei Yanrong,Pei Shengguang.Correlation between Survivin expression and laryngeal carcinoma:A Meta-analysis[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2017,37(06):965-973.
[35] Liu Guangyao,Liu Li.Expression and significance of survivin and c-MYC in gastric carcinoma[J].Cancer Progress,2017,15(12):1426-1429.

备注/Memo

备注/Memo:
四川省卫生和计划委员会资助项目(编号:J20160301)
更新日期/Last Update: 1900-01-01